Quetiapine Slows Next-Day Driving in 15 Sleep Apnea Patients After 50mg Trial
Updated
Updated · studyfinds.com · Jun 2
Quetiapine Slows Next-Day Driving in 15 Sleep Apnea Patients After 50mg Trial
3 articles · Updated · studyfinds.com · Jun 2
A randomized crossover trial in 15 adults found 50mg quetiapine worsened next-morning driving-simulator performance and reaction times versus placebo, despite an overnight sleep benefit.
Sleep measures improved on quetiapine: breathing interruptions fell to 20 an hour from 27, total sleep rose by more than 40 minutes, and wake time during the night dropped about 45%.
Morning impairment was substantial: attention lapses more than tripled, lane swerving increased, and simulated crashes were more frequent, though the study was too small to confirm crash risk statistically.
Four of 15 participants did not feel sleepier the next morning—and two felt more alert—even as objective tests showed worse performance, raising concern that some users may not recognize impairment.
Researchers advised avoiding driving or other safety-critical tasks for at least 9.5 hours after dosing; the warning matters because quetiapine was prescribed 10.7 million times in the U.S. in 2023, mostly at off-label low doses.
A new drug for sleep apnea is nearing approval. Could this be the safe alternative to risky off-label sleeping pills?
Doctors often prescribe pills for insomnia. Why is a safer, drug-free therapy so rarely used?
A popular insomnia pill impairs driving even if you feel alert. Are you taking a hidden risk every morning?
Next-Day Driving Impairment from Low-Dose Quetiapine: New Clinical Evidence, Off-Label Risks, and Policy Gaps Revealed by the 2026 Flinders Trial
Overview
A groundbreaking clinical trial led by Flinders University researchers, published in April 2026, revealed that low-dose quetiapine modestly improves sleep and breathing for people with obstructive sleep apnoea (OSA) who have trouble maintaining sleep. However, the study found that this benefit comes with a significant downside: quetiapine impairs next-day performance, raising serious concerns about driving safety. In response, the research team recommends better screening for sleep apnoea before prescribing sedating medications and urges clear warnings about next-day impairment, highlighting the need for safer, evidence-based alternatives to protect patient safety.